All News

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

Jesse Fann, MD, MPH, provided insights on the SCOPE trial, which evaluated technology-enhanced collaborative care for depression in patients undergoing active cancer treatment.

Ryan H. Moy, MD, PhD, noted that patients with early-onset esophagogastric cancer tend to have more advanced disease.

ECG changes and cardiac biomarkers were evaluated in patients with breast cancer to identify early markers of chemotherapy-induced cardiotoxicity.

The FDA has cleared an investigator-initiated investigational new drug application for a first-in-class AAV immuno-gene therapy in recurrent high-grade glioma.

Data from the phase 3 SENTRY trial showed a promising survival signal with selinexor plus ruxolitinib among patients with myelofibrosis.

Specialized LLMs, AI-assisted CT scans for early detection, and foundational models democratizing pathology are among emerging technologies in oncology care.

Looking ahead, local therapies and biomarkers may become even more important in the management of kidney cancer.

According to Yoanna S. Pumpalova, MD, both early-onset and later-onset colorectal cancers are genetically similar in terms of somatic mutations.

Venlafaxine was found to be an effective treatment for patients with breast cancer who are experiencing vasomotor symptoms.

Treatment with sunvozertinib showed improvement across all secondary end points among those with EGFR exon 20 insertion mutation–positive NSCLC.

COVID-19 and HIV reshaped cancer care, leading to delayed screenings, a surge in telehealth, mental health strain, and equity lessons, many of which clinicians still confront.

Experts explore the complexities of cannabis use, the financial impact, and best practices for administration in patients with cancer.

In the first-cycle of chemotherapy, patients under 40 were more likely to have higher rates of nausea/vomiting.

Two genitourinary oncologists discussed research examining germline platelet polygenic risk scores to predict survival outcomes in kidney cancer.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

Learn SCAC risk factors, rising trends, and new frontline retifanlimab chemoimmunotherapy, plus PD‑1 options and emerging checkpoint strategies.

Historically, 30% to 60% of AYA patients with cancer experience sexual dysfunction.

A panel of experts convened to explore the practical integration of BCMA-directed bispecific antibodies into clinical care for patients with multiple myeloma.

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

Three Neuroendocrine Tumor Research Foundation grant winners outlined research that aimed to deliver biology-driven strategies to patients.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

It is unlikely that guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

The resubmission occurred after discussions with the FDA in January 2026, where the agency requested additional data to support its review.

Patients with high-risk or intermediate-risk disease may benefit from allogeneic stem cell transplantation as a potentially “curative approach.”

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

The NHS-Galleri study showed that multi-cancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

Rusfertide could become a part of every patient’s treatment history for polycythemia vera, according to Andrew Kuykendall, MD.

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.